Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide + trastuzumab in HER2-positive, androgen receptor-positive advanced breast cancer
2013-000093-29Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide and trastuzumab in breast cancer, sponsored by Astellas Pharma. Primary endpoint: Clinical benefit rate. Started Mar 2014; status: completed.
02
Drugs
enzalutamidetrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-000093-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000093-29.